Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab plus platinum-etoposide versus platinum-etoposide in first-line extensive-stage small-cell lung cancer
NL-OMON50493Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Overall survival and Progression-free survival. Started Jul 2017; status: active, not recruiting.
02
Drugs
durvalumabtremelimumabetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON50493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50493.